Compare Enveric Biosciences Inc (ENVB) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Alphabet Inc Class A — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Alphabet Inc Class A trades at $350.15 (market cap $4.27T). The key difference: Alphabet Inc Class A is far larger — about 638266.1× Enveric Biosciences Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Alphabet Inc Class A for 85 Days on average.
| ENVB | GOOGL | |
|---|---|---|
Market Cap | $6.69M | $4.27T |
Volume | 41,141 | 20,474,140 |
Sector | Health | Media |
52-Week High | $10.80 | $402.62 |
52-Week Low | $1.27 | $236.59 |
Typical Hold Time | 14 Days | 85 Days |
Enterprise Value | -$1.60M | $4.16T |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Alphabet (GOOGL) trades at $348.29, up 0.18% today, with a bullish technical outlook supported by moving averages and key support at $346. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.11 versus $2.87 expected, and fundamentals show robust revenue growth to $402.84 billion in 2025 and a net income margin of 32.8%. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube subscription price increases.
The outlook remains positive with an analyst consensus price target of $431.83, implying significant upside. Key opportunities include AI infrastructure expansion and revenue diversification, while risks involve antitrust scrutiny and competitive pressures. Institutional sentiment is strongly bullish, with 86.75% of analysts rating the stock a buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
